Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Sipuleucel-T with or without Continuing New Hormonal Agents (NHA) for Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer with PSA Progression while on NHA and LHRH Analog

Trial Status: active

This phase II trial compares the effect of sipuleucel-T with or without continuing new hormonal agents (NHA)(enzalutamide, apalutamide or abiraterone) for treatment of patients with castration-resistant prostate cancer that has spread from where it first started (primary site) to other places in the body (metastatic) who experience prostate specific antigen (PSA) progression while on NHA and luteinizing hormone-releasing hormone (LHRH) analog. Sipuleucel-T works by treating cells taken from a patient with prostate cancer and combining them with a growth factor. The cells are given back to the patient and may stimulate T cells to kill prostate cancer cells. Hormonal agents such as enzalutamide, apalutamide or abiraterone plus prednisone as well as LHRH analogs work to lower the amount of testosterone made by the body. This may help stop the growth of prostate cancer cells that need testosterone to grow. Giving sipuleucel-T while continuing new hormonal agents may kill more prostate cancer cells in patients with metastatic castration resistant prostate cancer with PSA progression while on NHA and LHRH analog.